Nonalcoholic fatty liver disease (NAFLD) has been recognized as a major health burden.
The high prevalence of NAFLD is probably due to the contemporary epidemics of obesity …

Non‐alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from
simple steatosis through steatohepatitis (NASH) to increasing fibrosis and eventual cirrhosis …

Tumor necrosis factor α (TNFα) is known to be involved in dysregulation of hepatic lipid
metabolism and insulin signaling. However, whether TNFα also plays a casual role in the …

OBJECTIVES: The pharmacologic approach to disease management has not (as of yet)
demonstrated safety and efficacy in nonalcoholic fatty liver disease (NAFLD). The current …

Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar
pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH …

Patients with non-alcoholic fatty liver disease are characterised by a decreased n-3/n-6
polyunsaturated fatty acid (PUFA) ratio in hepatic phospholipids. The metabolic …

Nonalcoholic fatty liver disease is one of the most common liver diseases. l-Tryptophan and
its metabolite serotonin are involved in hepatic lipid metabolism and inflammation. However …

Abstract Plasminogen activator inhibitor-1 (PAI-1) is an acute-phase protein known to be
involved in alcoholic liver disease and hepatic fibrosis. In the present study, the hypothesis …

Introduction: Non-alcoholic fatty liver disease (NAFLD) is becoming one of the most common
causes of chronic liver disease worldwide. The economic and social cost of disease is very …

CONCEPTS—Gerald Reaven (Stanford, CA) opened the meeting with a discussion of the
implications of insulin resistance and of the interrelationships between hyperinsulinemia …